Population-based studies have established that long-term intake of non-steroidal anti-inflammatory drugs (NSAIDs), compounds that inhibit the enzymatic activity of cyclooxygenase (COX), reduces the relative risk for developing colorectal cancer. These studies led to the identification of a molecular target, COX-2, that is involved in tumour promotion during colorectal cancer progression. Recent studies in humans indicate that therapy with specific COX-2 inhibitors might be an effective approach to colorectal cancer prevention and treatment.
Population-based studies have established that chronic intake of non-selective non-steroidal anti-inflammatory drugs (NSAIDs) reduces the relative risk for developing colorectal cancer. In randomized clinical trials, administration of a NSAID reduces intestinal polyp burden in patients with familial adenomatous polyposis (FAP).
Traditional NSAIDs inhibit the activity of cyclooxygenases 1 and 2 (COX-1 and COX-2), enzymes that catalyse the rate-limiting step in the conversion of arachidonate to prostanoids. Selective COX-2 inhibitors have now been developed and these compounds retain the anti-inflammatory activity, but cause fewer gastrointestinal side effects, than non-selective NSAIDs.
In rodent models of intestinal neoplasia, both non-selective and COX-2-selective NSAIDs are potent suppressors of colorectal cancer cell growth.
The anti-tumour activity of NSAIDs has been attributed to both COX-dependent and COX-independent mechanisms. The non-COX effects are probably relevant when high doses of NSAIDs are used and may involve inhibition of the NF-κB pathway, the peroxisome proliferator-activated receptor (PPAR) family of nuclear hormone receptors, or direct actions on certain components of the apoptotic machinery.
The most direct evidence implicating a pro-oncogenic function for COX-2 has come from genetic studies in mice. For example, ApcΔ716 mice (a model of FAP) have an 86% reduction in polyp number in a Cox-2−/− background compared with control animals.
The expression of COX-2, but not COX-1, is elevated in many colorectal cancers and the protein has been localized to both stromal and epithelial compartments. At least one mechanism by which elevated COX-2 promotes carcinogenesis is through stimulation of tumour-associated angiogenesis.
Limited work has been done to identify the specific prostaglandin (PG) subtypes and receptors downstream of COX-2 that are involved in colorectal cancer progression. Some experiments have indicated that PGE2 can promote colorectal cancer growth, in part through activation of the PGE2 receptor subtype EP1.
Recently, selective COX-2 inhibitors were shown to reduce polyp burden in individuals with FAP. Ongoing clinical trials are examining the ability of COX-2 inhibitors, alone or in combination with other therapeutic agents, to either prevent polyp formation or treat existing colorectal tumours in the general population.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Future Journal of Pharmaceutical Sciences Open Access 29 July 2020
Cytosolic phospholipase A2-α participates in lipid body formation and PGE2 release in human neutrophils stimulated with an l-amino acid oxidase from Calloselasma rhodostoma venom
Scientific Reports Open Access 03 July 2020
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Greenlee, R. T., Murray, T., Bolden, S. & Wingo, P. A. Cancer statistics, 2000. CA Cancer J. Clin. 50, 7–33 (2000).
Herschman, H. R. Prostaglandin synthase 2. Biochim. Biophys, Acta 1299, 125–140 (1996).
DuBois, R. N. et al. Cyclooxygenase in biology and disease. FASEB J. 12, 1063–1073 (1998).
Herschman, H. R., Xie, W. & Reddy, S. Inflammation, reproduction, cancer and all that...: the regulation and role of the inducible prostaglandin synthase. Bioessays 17, 1031–1037 (1995).
Smith, W. L., DeWitt, D. L. & Garavito, R. M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69, 145–182 (2000).
Raz, A., Wyche, A., Siegel, N. & Needleman, P. Regulation of fibroblast cyclooxygenase synthesis by interleukin-1. J. Biol. Chem. 263, 3022–3028 (1988).
Fu, J. Y., Masferrer, J. L., Seibert, K., Raz, A. & Needleman, P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. 265, 16737–16740 (1990).
Xie, W., Chipman, J., Robertson, D., Erikson, R. & Simmons, D. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl Acad. Sci. USA 88, 2692–2696 (1991).
Kujubu, D. A., Fletcher, B. S., Varnum, B. C., Lim, R. W. & Herschman, H. R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 266, 12866–12872 (1991).
Smith, W. L., Garavito, R. M. & DeWitt, D. L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and-2. J. Biol. Chem. 271, 33157–33160 (1996).
Masferrer, J. L. et al. Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl Acad. Sci. USA 91, 3228–3232 (1994).This study established 'proof of principle' that selective inhibition of COX-2 offered the anti-inflammatory activity, but lacked the gastrointestinal side effects of non-selective NSAIDs.
Marnett, L. J. & Kalgutkar, A. S. Cyclooxygenase 2 inhibitors: discovery, selectivity and the future. Trends Pharmacol. Sci. 20, 465–469 (1999).
Laine, L. et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 117, 776–783 (1999).
Emery, P. et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 354, 2106–2111 (1999).
Waddell, W. R. & Loughry, R. W. Sulindac for polyposis of the colon. J. Surg. Oncol. 24, 83–87 (1983).The first clinical observation that NSAIDs could cause the regression of intestinal polyps.
Giovannucci, E. et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. 121, 241–246 (1994).
Giovannucci, E. et al. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333, 609–614 (1995).
Thun, M. J., Namboodiri, M. M. & Heath, C. W. J. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325, 1593–1596 (1991).The largest and most widely cited prospective population-based study that identified a correlation between NSAID use and a reduction in the relative risk of colorectal cancer.
DuBois, R. N., Giardiello, F. M. & Smalley, W. E. Nonsteroidal anti-inflammatory drugs, eicosanoids and colorectal cancer prevention. Gastroenterology Clinics N. Am. 25, 773–791 (1996).
Kinzler, K. W. et al. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 251, 1366–1370 (1991).
Labayle, D. et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101, 635–639 (1991).
Nugent, K. P., Farmer, K. C., Spigelman, A. D., Williams, C. B. & Phillips, R. K. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg. 80, 1618–1619 (1993).
Giardiello, F. M. et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328, 1313–1316 (1993).This paper and references 21 and 22 were the first to demonstrate in a randomized, double-blind placebo-controlled clinical trial that the NSAID sulindac could cause regression of polyps in patients with FAP.
Steinbach, G. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946–1952 (2000).The first study to show that a selective COX-2 inhibitor could cause polyp regression in individuals with FAP.
Oshima, M. et al. Suppression of intestinal polyposis in ApcΔ716 knockout mice by inhibition of prostaglandin endoperoxide synthase-2 (COX-2). Cell 87, 803–809 (1996).The first study to offer direct genetic evidence that COX-2 is important for intestinal polyp development by documenting that ApcΔ716 mice show an 86% reduction in polyp number in a COX-2−/− background compared with control animals.
Williams, C. S., Tsujii, M., Reese, J., Dey, S. K. & DuBois, R. N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105, 1589–1594 (2000).Provides genetic evidence that COX-2 in the tumour stroma can promote carcinoma cell growth.
Chulada, P. C. et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60, 4705–4708 (2000).
Liu, C. H. et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. 276, 18563–18569 (2001).The first study to show that overexpression of COX2 is sufficient to induce cellular transformation.
Neufang, G., Furstenberger, G., Heidt, M., Marks, F. & Muller-Decker, K. Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc. Natl Acad. Sci. USA. 98, 7629–7634 (2001).
Zhang, X., Morham, S. G., Langenbach, R. & Young, D. A. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J. Exp. Med. 190, 445–450 (1999).Describes the first genetic evidence that high doses of NSAIDs can induce apoptosis independently of COX-1 or COX-2.
Hanif, R. et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 52, 237–245 (1996).
Williams, C. S. et al. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 60, 6045–6051 (2000).
Jacoby, R. F., Seibert, K., Cole, C. E., Kelloff, G. & Lubet, R. A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res. 60, 5040–5044 (2000).
Reddy, B. S. et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 60, 293–297 (2000).
Kopp, E. & Ghosh, S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265, 956–959 (1994).
Yamamoto, Y., Yin, M. J., Lin, K. M. & Gaynor, R. B. Sulindac inhibits activation of the NF-kappaB pathway. J. Biol. Chem. 274, 27307–27314 (1999).
Yin, M. J., Yamamoto, Y. & Gaynor, R. B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396, 77–80 (1998).
Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M. & Kliewer, S. A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272, 3406–3410 (1997).
He, T. C., Chan, T. A., Vogelstein, B. & Kinzler, K. W. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99, 335–345 (1999).
Park, B. H., Vogelstein, B. & Kinzler, K. W. Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells. Proc. Natl Acad. Sci. USA 98, 2598–2603 (2001).
Zhang, L., Yu, J., Park, B. H., Kinzler, K. W. & Vogelstein, B. Role of BAX in the apoptotic response to anticancer agents. Science 290, 989–992 (2000).
Eberhart, C. E. et al. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107, 1183–1188 (1994).
Sano, H. et al. Expression of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res. 55, 3785–3789 (1995).
Kargman, S. et al. Expression of prostaglandin G/H synthase-1 and-2 protein in human colon cancer. Cancer Res. 55, 2556–2559 (1995).
Williams, C. W. et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 111, 1134–1140 (1996).
DuBois, R. N., Radhika, A., Reddy, B. S. & Entingh, A. J. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 110, 1259–1262 (1996).
Shao, J. et al. Coordinate regulation of cyclooxygenase-2 and TGF-β1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis 20, 185–191 (1999).
Kutchera, W. et al. Prostaglandin H synthase-2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc. Natl Acad. Sci. USA 93, 4816–4820 (1996).
Karnes, W. E. et al. Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res. 58, 5473–5477 (1998).
Shattuck-Brandt, R. L., Lamps, L. W., Heppner-Goss, K. J., DuBois, R. N. & Matrisian, L. M. Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms. Mol. Carcinog. 24, 177–187 (1999).
Hull, M. A. et al. Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. Br. J. Cancer 79, 1399–1405 (1999).
Shattuck-Brandt, R. L. et al. Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(−/−) mice. Gastroenterology 118, 337–345 (2000).
Chapple, K. S. et al. Localization of cyclooxygenase-2 in human sporadic colorectal adenoma. Am. J. Pathol. 156, 545–553 (2000).
Bamba, H. et al. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int. J. Cancer 83, 470–475 (1999).
Masferrer, J. L. et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60, 1306–1311 (2000).Provides comprehensive evidence that COX-2- selective inhibitors have anti-angiogenic properties owing to the inhibition of endothelial-derived COX-2 activity.
Kinzler, K. W. & Vogelstein, B. Landscaping the cancer terrain. Science 280, 1036–1037 (1998).
Sheng, H. et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 99, 2254–2259 (1997).The first study to show that COX-2 inhibitors could inhibit the growth of established colorectal carcinoma cells in vivo using the nude mouse xenograft model.
Tsujii, M. & DuBois, R. N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 83, 493–501 (1995).The first study to document that overexpression of COX2 can activate pro-oncogenic pathways.
Tsujii, M., Kuwano, S. & DuBois, R. N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl Acad. Sci. USA 94, 3336–3340 (1997).
Tsujii, M. et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93, 705–716 (1998).
Chinery, R. et al. Prostaglandin J2 and 15-deoxy-delta12,14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Res. 59, 2739–2746 (1999).
Majima, M. et al. Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants. Jpn. J. Pharmacol. 75, 105–114 (1997).
Majima, M. et al. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br. J. Pharmacol. 130, 641–649 (2000).
Daniel, T. O., Liu, H., Morrow, J. D., Crews, B. C. & Marnett, L. J. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. 59, 4574–4577 (1999).
Jones, M. K. et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nature Med. 5, 1418–1423 (1999).
Sugimoto, Y., Narumiya, S. & Ichikawa, A. Distribution and function of prostanoid receptors: studies from knockout mice. Prog. Lipid Res. 39, 289–314 (2000).
Morita, I. et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and-2. J. Biol. Chem. 270, 10902–10908 (1995).
Gupta, R. A. et al. Prostacyclin-mediated activation of PPARδ in colorectal cancer. Proc. Natl Acad. Sci. USA 97, 13275–13280 (2000).
Forman, B. M., Chen, J. & Evans, R. M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl Acad. Sci. USA 94, 4312–4317 (1997).
Forman, B. M. et al. 15-Deoxy-δ 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83, 803–812 (1995).
Kliewer, S. A. et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83, 813–819 (1995).
Bhattacharya, M. et al. Nuclear localization of prostaglandin E2 receptors. Proc. Natl Acad. Sci. USA 95, 15792–15797 (1998).
Rigas, B., Goldman, I. S. & Levine, L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 122, 518–523 (1993).
Giardiello, F. M. et al. Prostaglandin levels in human colorectal mucosa: effect of sulindac in patients with familial adenomatous polyposis (FAP). Gastroenterology 112, A568 (1997).
Sheng, H., Shao, J., Morrow, J., Beauchamp, R. D. & DuBois, R. N. Modulation of apoptosis by prostaglandin treatment in human colon cancer cells. Cancer Res. 58, 362–366 (1998).
Sheng, H., Shao, J., Washington, M. K. & DuBois, R. N. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem. 12, 12 (2001).
Adam, L., Mazumdar, A., Sharma, T., Jones, T. R. & Kumar, R. A three-dimensional and temporo-spatial model to study invasiveness of cancer cells by heregulin and prostaglandin E2. Cancer Res. 61, 81–87 (2001).
Watanabe, K. et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res. 59, 5093–5096 (1999).This study provides both genetic and pharmacological evidence that the PGE 2 receptor subtype EP1 promotes colorectal cancer development.
Watanabe, K. et al. Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice. Cancer Lett. 156, 57–61 (2000).
Gilroy, D. W. et al. Inducible cyclooxygenase may have anti-inflammatory properties. Nature Med. 5, 698–701 (1999).
Farrow, D. C. et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev. 7, 97–102 (1998).
Coogan, P. F. et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol. Biomarkers Prev. 9, 119–123 (2000).
Sharpe, C. R. et al. Nested case-control study of the effects of non-steroidal anti- inflammatory drugs on breast cancer risk and stage. Br. J. Cancer 83, 112–120 (2000).
Egan, K. M., Stampfer, M. J., Giovannucci, E., Rosner, B. A. & Colditz, G. A. Prospective study of regular aspirin use and the risk of breast cancer. J. Natl Cancer Inst. 88, 988–993 (1996).
Norrish, A. E., Jackson, R. T. & McRae, C. U. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int. J. Cancer 77, 511–515 (1998).
Castelao, J. E., Yuan, J. M., Gago-Dominguez, M., Yu, M. C. & Ross, R. K. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br. J. Cancer 82, 1364–1369 (2000).
Rosenberg, L. et al. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 9, 933–937 (2000).
Cramer, D. W. et al. Over-the-counter analgesics and risk of ovarian cancer. Lancet 351, 104–107 (1998).
Buckman, S. Y. et al. COX2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 19, 723–729 (1998).
Wolff, H. et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58, 4997–5001 (1998).
Hwang, D., Scollard, D., Byrne, J. & Levine, E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl Cancer Inst. 90, 455–460 (1998).
Gupta, S., Srivastava, M., Ahmad, N., Bostwick, D. G. & Mukhtar, H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42, 73–78 (2000).
Mohammed, S. I. et al. Expression of cyclooxygenase-2 (COX2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res. 59, 5647–5650 (1999).
Tucker, O. N. et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 59, 987–990 (1999).
Chan, G. et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 59, 991–994 (1999).
Grubbs, C. J. et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 60, 5599–5602 (2000).
Fischer, S. M. et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol. Carcinog. 25, 231–240 (1999).
Kapitanovic, S. et al. The expression of p185 (HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 112, 1103–1113 (1997).
Markowitz, S. D. et al. Growth stimulation by coexpression of transforming growth factor-alpha and epidermal growth factor-receptor in normal and adenomatous human colon epithelium. J. Clin. Invest. 86, 356–362 (1990).
Torrance, C. J. et al. Combinatorial chemoprevention of intestinal neoplasia. Nature Med. 6, 1024–1028 (2000).This group showed that ApcMin mice treated with the NSAID sulindac and an ERBB inhibitor leads to complete suppression of polyp formation, indicating that such combinatorial regimens might offer hope for cancer chemoprevention.
Mann, M. et al. Targeting cyclooxygenase 2 and her-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120, 1713–1719 (2001).
Kinzler, K. W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159–170 (1996).
Sinicrope, F. A. et al. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology 117, 350–358 (1999).
Raab, Y., Sundberg, C., Hallgren, R., Knutson, L. & Gerdin, B. Mucosal synthesis and release of prostaglandin E2 from activated eosinophils and macrophages in ulcerative colitis. Am. J. Gastroenterol. 90, 614–620 (1995).
Hendel, J. & Nielsen, O. H. Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. Am. J. Gastroenterol. 92, 1170–1173 (1997).
Newberry, R. D., Stenson, W. F. & Lorenz, R. G. Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nature Med. 5, 900–906 (1999).
Reuter, B. K., Asfaha, S., Buret, A., Sharkey, K. A. & Wallace, J. L. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J. Clin. Invest. 98, 2076–2085 (1996).
Morteau, O. et al. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J. Clin. Invest. 105, 469–478 (2000).
Vane, J. R. History of aspirin and its mechanism of action. Stroke 21, IV12–IV23 (1990).
Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231, 232–235 (1971).
Lal, G. & Gallinger, S. Familial adenomatous polyposis. Semin. Surg. Oncol. 18, 314–323 (2000).
Groden, J. et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66, 589–600 (1991).
Cottrell, S., Bicknell, D., Kaklamanis, L. & Bodmer, W. F. Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet 340, 626–630 (1992).
Moser, A. R., Pitot, H. C. & Dove, W. F. A dominant mutation that predisposes to mutiple intestinal neoplasia in the mouse. Science 247, 322–325 (1990).
Su, L. K. et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the Apc gene. Science 256, 668–670 (1992).
Lijinsky, W. Intestinal cancer induced by N-nitroso compounds. Toxicol. Pathol. 16, 198–204 (1988).
Boolbol, S. K. et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 56, 2556–2560 (1996).
Beazer-Barclay, Y. et al. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 17, 1757–1760 (1996).
Jacoby, R. F. et al. Chemoprevention of spontaneous intestinal adenomas in the ApcMin mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res. 56, 710–714 (1996).
Oshima, M. et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 61, 1733–1740 (2001).
Reddy, B. S., Rao, C. V., Rivenson, A. & Kelloff, G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14, 1493–1497 (1993).
Kawamori, T., Rao, C. V., Seibert, K. & Reddy, B. S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58, 409–412 (1998).The first study to document that a selective COX-2 inhibitor could reduce tumour multiplicity and incidence in the AOM-rat model of colorectal cancer.
Yoshimi, N. et al. Chemopreventive effect of N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, in rat colon carcinogenesis induced by azoxymethane. Jpn. J. Cancer Res. 90, 406–412 (1999).
Fukutake, M. et al. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis 19, 1939–1942 (1998).
Goldman, A. P. et al. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 19, 2195–2199 (1998).
Dormond, O. Foletti, A., Paroz, C. & Ruegg, C. NSAIDs inhibit αVβ3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration, and angiogenesis. Nature Med. 9, 1041–1047 (2001).
Sonoshita, M. et al. Acceleration of intestinal polyposis through prostaglandin EP2 in ApcΔ716 knockout mice. Nature Med. 9, 1048–1051 (2001).
Our work is supported in part from United States Public Health Services Grants. R.N.D is a recipient of a VA (Veterans Affairs) Research Merit Grant and is the Mina C. Wallace Professor of Cancer Prevention. We also thank the T.J. Martell Foundation and the NCCRA (National Colorectal Cancer Research Alliance) for generous support.
Any of a class of hormone-like, lipid-soluble regulatory molecules constructed from polyunsaturated fatty acids such as arachidonate. These molecules participate in diverse body functions, such as smooth muscle contraction and relaxation, vasodilation and regulation of kidney function.
- ARACHADONIC ACID
A 20-carbon polyunsaturated fatty acid usually found esterified in membrane glycerophosophlipids at the sn-2 position. The phospholipase A2 (PLA2) family of enzymes catalyse the release of arachidonic acid from the membrane in response to various stimuli. The lipoxygenase and cyclooxygenase enzymes use liberated arachadonic acid as a substrate to generate eicosanoids.
A form of bioregulation in which a secretory factor affects only the cell from which it was secreted.
A form of bioregulation in which a secretion produced by one cell type in a tissue diffuses through the tissue and affects another cell type in the same tissue.
- PHORBOL ESTERS
Polycyclic compounds isolated from croton oil that are potent co-carcinogens or tumour promoters. They are diacylglycerol analogues and irreversibly activate protein kinase C.
- MURINE MAMMARY TUMOUR VIRUS (MMTV) PROMOTER/ENHANCER
MMTV causes mammary adenocarcinoma in infected mice and selectively replicates in the alveolar epithelial cells of the mammary gland. The MMTV promoter/enhancer has often been used to direct the expression of transgenes specifically in the mammary gland.
A transcription factor involved in regulating the expression of inflammatory and growth- control genes in several cells and tissues. Various stimuli (for example, tumour necrosis factor, phorbol esters and bacterial lipopolysaccharide) allow NF-κB to enter the nucleus and bind to regulatory elements of target genes.
- PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPARS)
A family (subtypes α, δ and γ) of ligand-activated transcription factors that are members of the nuclear-hormone-receptor superfamily. PPARs have important functions in fatty-acid catabolism and storage, and endogenous PPAR ligands include fatty acids and certain fatty acid metabolites.
- MATRIX METALLOPROTEINASES
A family of proteolytic enzymes that degrade the extracellular matrix and have important roles in tissue remodelling and tumour metastasis.
- PI3K/AKT PATHWAY
The phosphatidylinositol 3- kinase (PI3K) family of enzymes are activated in response to a wide variety of stimuli and catalyse the phophorylation of inositol lipds at the D-3 position of the inositol ring. These phosphoinositides act as second messengers; a primary target is the serine/threonine kinase AKT (protein kinase B). Activated AKT phosphorylates several cellular targets, including proteins involved in cell survival, proliferation and migration.
The ERBB/HER family of growth factor receptors have vital roles in the morphogenesis and maintenance of epithelial organs. heregulin-β1 is a ligand for ERBB/HER receptor subtypes ERBB3/HER-3 and ERBB4/HER-4.
- IMMEDIATE EARLY GENES
A category of genes that represent the first transcriptional response of a cell to certain stimuli (for example, growth factors). These genes are generally induced within 15 minutes of stimulation, and the induction does not require de novo protein synthesis.
A surgical procedure that involves the excision of the colon and rectum followed by the formation of an ileoanal reservoir (pouch).
- CHROMOSOMAL INSTABILITY (CIN)
Describes aneuploid tumours in which whole chromosomes or large segments of chromsomes are gained and lost.
- MICROSATELLITE INSTABILITY (MIN)
Describes diploid tumours in which genetic instability is due to a high mutation rate, primarily in short nucleotide repeats. Cancers with the MIN phenotype are associated with defects in DNA mismatch- repair genes.
- INFLAMMATORY BOWEL DISEASE (IBD)
A general term that refers to chronic inflammatory disorders of the intestine, such as Crohn's disease and ulcerative colitis. The inflammation causes ulceration of the intestinal lining leading to rectal bleeding, diarrhoea and abdominal pain, and increases the risk of intestinal cancer. IBD is an autoimmune disease and is thought to have a significant genetic component.
About this article
Cite this article
Gupta, R., DuBois, R. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1, 11–21 (2001). https://doi.org/10.1038/35094017
This article is cited by
Cancer Causes & Control (2022)
Future Journal of Pharmaceutical Sciences (2020)
MicroRNA binding site polymorphism in inflammatory genes associated with colorectal cancer: literature review and bioinformatics analysis
Cancer Gene Therapy (2020)
Journal of Gastrointestinal Cancer (2020)
Acute changes in colonic PGE2 levels as a biomarker of efficacy after treatment of the Pirc (F344/NTac-Apc am1137) rat with celecoxib
Inflammation Research (2020)